A double-blind, randomized, placebo-controlled, parallel-group study of ranolazine SR at a dose of 1000 mg twice a day in patients with chronic angina who remain symptomatic despite treatment with amlodipine 10 mg once a day
Phase of Trial: Phase III
Latest Information Update: 14 Jan 2008
At a glance
- Drugs Ranolazine (Primary)
- Indications Angina pectoris
- Focus Therapeutic Use
- Acronyms ERICA
- Sponsors Gilead Sciences
- 14 Jan 2008 Status changed from in progress to completed.
- 23 Oct 2005 New trial record.